 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

For the last three days, A.I.dvisor has detected that NPCE's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Neuropace (NPCE, $13.2) Aroon Indicator entered a Downtrend on March 28, 2024.

This indicator may be signaling that NPCE's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Neuropace (NPCE, $13.2) entered Downtrend as Momentum indicator drops below 0 level on Mar 28, 2024

Neuropace (NPCE, $13.61) Aroon Indicator entered a Downtrend on March 27, 2024.

MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced...

NeuroPace to Present at the Needham 23rd Annual Healthcare Conference

Neuropace (NPCE, $13.33) Aroon Indicator entered a Downtrend on March 26, 2024.

Neuropace (NPCE, $13.82) Aroon Indicator entered a Downtrend on March 22, 2024.

Neuropace (NPCE, $13.56) Aroon Indicator entered a Downtrend on March 21, 2024.

Neuropace (NPCE, $13.64) Aroon Indicator entered a Downtrend on March 20, 2024.

Neuropace (NPCE, $13.45) Aroon Indicator entered a Downtrend on March 19, 2024.

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Wells Fargo upgrades NeuroPace to Overweight, raises price target to $20

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.

Volume (M)	65,350.00
52-Wk High	$18.15
52-Wk Low	$3.80

NPCE NeuroPace Inc

About

Feed

News

Earnings

Fundamentals